loader2
Login Open ICICI 3-in-1 Account
Open ICICI 3-in-1 Account

Fortis Healthcare Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Fortis Healthcare Ltd. 12 Nov 2025 11:49 AM
Result PDF

Q2FY26 Quarterly Result Announced for Fortis Healthcare Ltd.

Healthcare Facilities company Fortis Healthcare announced Q2FY26 results

  • Consolidated Revenues at Rs 2,331 crore, up 17.3% YoY.
  • Operating EBITDA Margin at 23.9% vs 21.9% in Q2FY25.
  • Profit after Tax at Rs 329 crore, up 70.3% YoY.
  • Hospital Business Revenues at Rs 1,974 crore, up 19.3% YoY.
  • Operating EBITDA margin at 22.9% vs 21.4% in Q2FY25.

Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare said: “We have maintained a healthy growth momentum across both our hospital and diagnostics businesses. In the hospital segment, key specialties such as Oncology and Renal Sciences grew by 29% and 22%, respectively, compared to the same period last year. Our growth and expansion strategy is accelerating on multiple fronts. The company recently entered into a lease agreement for a ~200-bedded multi-specialty hospital in Greater Noida, a facility that we had previously been managing under an O&M arrangement. This expands our presence in Delhi NCR to ~2,100 beds. The integration of Gleneagles units under the O&M arrangement with Fortis is progressing well and we have also made our foray in Lucknow with an O&M arrangement for a 550 bedded super specialty hospital to be constructed by the Ekana Group.”

“In the diagnostics business, we continue to witness a buoyant recovery in both revenue and EBITDA margin and expect this positive momentum to continue going forward.”

Result PDF

Result PDF

Healthcare Facilities company Fortis Healthcare announced Q1FY26 results

  • Revenue: Rs 2,167 crore compared to Rs 1,859 crore during Q1FY25, change 16.6%.
  • EBITDA: Rs 491 crore compared to Rs 343 crore during Q1FY25, change 43.2%.
  • EBITDA Margin: 18.4% for Q1FY26.
  • PAT: Rs 260 crore compared to Rs 166 crore during Q1FY25, change 56.8%.
  • EPS: Rs 2.20 for Q1FY26.

Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare said: “We have witnessed a healthy start to the financial year, as demonstrated in our Q1 earnings for both hospital and diagnostic businesses. The recently executed O&M services agreement with Gleneagles India expands our geographic footprint and provides an opportunity to leverage our combined strengths to optimize operations and enhance efficiencies. The company also consummated the acquisition of Shrimann Superspecialty Hospital in Jalandhar, further strengthening our presence in Punjab region with approx. 1,000 beds.”

Result PDF

Healthcare Facilities company Fortis Healthcare announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Consolidated Revenues up 12.4% to Rs 2,007 crore
  • Operating EBITDA up 14.3% to Rs 435 crore, 21.7% Margin (vs Q4FY24 at 21.3%)
  • Hospital Business Revenues up 14.2% to Rs 1,701 crore
  • Operating EBITDA up 11.7% to Rs 372 crore, 21.9% Margin (vs Q4FY24 at 22.4%)

FY25 Financial Highlights:

  • Consolidated Revenues up 12.9% to Rs 7,783 crore
  • Operating EBITDA up 25.3% to Rs 1,588 crore, 20.4% Margin (vs FY24 at 18.4%)
  • Hospital Business Revenues up 14.8% to Rs 6,528 crore
  • Operating EBITDA up 26.6% to Rs 1,339 crore, 20.5% Margin (vs FY24 at 18.6%)

Commenting on the results for the quarter and the year, Ashutosh Raghuvanshi, MD and CEO, Fortis Healthcare stated, “We have witnessed another year of healthy growth and margin improvement. Noticeable developments during the year included the successful acquisition of the ‘Fortis’ brand and trademarks and our foray into Jalandhar with the signing of definitive agreements in February 2025 to acquire the Shrimann Superspecialty Hospital. The transaction enables us to further strengthen our presence in the Punjab region from approximately 800 beds across four facilities to over 1,000 beds. Aligned to our focus on portfolio rationalization, we divested the business operations of Richmond Road Hospital, Bengaluru in December 2024. Given the strength of our balance sheet, we continue to actively pursue further inorganic growth opportunities in our focus geographic clusters.”

He further added “In FY25, our hospital business contributed 84% to consolidated revenue compared to 82% in FY24. Revenue from focus specialties comprising Oncology, Neurosciences, Cardiac Sciences, Gastroenterology, Orthopedics and Renal Sciences grew 16% YoY and contributed 62% to overall hospital business revenues. The Company consolidated its shareholding in Agilus to 89.2% post the acquisition of 31.5% stake from the PE investors. We have witnessed a steady improvement in the diagnostics business EBITDA margins (excluding one-offs) at 22.0% in FY25 compared to 19.6% in FY24. The new brand is being well accepted and gaining prominence; placing the business in a better position to drive business expansion and enhance performance metrics.”

Result PDF

Healthcare Facilities company Fortis Healthcare announced Q3FY25 results

  • Q3FY25 consolidated revenues were at Rs 1,928.3 crore, up 14.8% versus Q3FY24. The operating margins for the quarter were 19.4%, versus 16.9% in the corresponding previous period.
  • Q3FY25 hospital business revenues grew 16.8% to Rs 1,623.1 crore as compared to Rs 1,389.5 crore in Q3FY24. Operating margins stood at 20.0% for the period versus 18.0% in the corresponding previous period.
  • Q3FY25 diagnostic business net revenue were at Rs 305.2 crore versus Rs 290.2 crore in Q3FY24. Operating margins stood at 16.2% for the period versus 11.4% in the corresponding previous period. Excluding one offs, the operating EBITDA margins stood at 23.9% versus 20.8% in Q3FY24.
  • The Company’s net debt as of 31st December 2024 stood at Rs 644 crore with a Net Debt to EBITDA of 0.41x as compared to the 0.45x as on 31st December 2023 (basis Q3 annualized EBITDA). Net debt to equity was at 0.07x versus 0.06x as on 31st December 2023.

Ashutosh Raghuvanshi, MD and CEO, Fortis Healthcare stated, “We have continued our positive momentum in Q3 with the hospital business contributing approximately 84% to our consolidated revenue and 87% to our consolidated EBITDA. As part of the Company’s portfolio rationalization strategy, we divested business operations of Richmond Road Hospital, Bangalore in December 2024. This divestment supports our focus on improving overall profitability and margins. Leveraging our robust balance sheet, we continue to actively pursue further inorganic growth opportunities in our focus geographic clusters.”

He further added “Revenue from focus specialties comprising Oncology, Neurosciences, Cardiac Sciences, Gastroenterology, Orthopedics and Renal Sciences contributed 62% to overall hospital business revenues. Among our key specialties, Oncology grew by a strong 30% led by growth of 44% in Hematology and Bone Marrow Transplant, compared to the same period last year. On the diagnostics business, we consolidated our stake by acquiring 31.5% stake from the PE investors, with the Company now holding 89.2% shareholding in Agilus. The diagnostics business performance continues to recover, with an EBITDA margin (excluding one offs) of 21.3%, compared to 18.3% in Q3FY24. However, the business is still impacted by rebranding expenses which we expect will taper off towards the end of the fiscal”.

Result PDF

Healthcare Facilities company Fortis Healthcare announced Q2FY25 results

Financial Highlights:

  • Q2FY25 consolidated revenues were at Rs 1,988.4 crore, up 12.3% versus Q2FY24. The operating margins for the quarter were 21.9%, versus 18.6% in the corresponding previous period.
  • Q2FY25 hospital business revenues grew 13.9% to Rs 1,654.7 crore as compared to Rs 1,452.6 crore in Q2FY24. Operating margins stood at 21.4% for the period versus 18.4% in the corresponding previous period.
  • Q2FY25 diagnostic business gross revenues were at Rs 3725 crore versus Rs 360.3 crore in Q2FY24.

Other Highlights:

  • Operating EBITDA margins (basis gross revenues) stood at 21.5% versus 17.2% in Q2FY24. Excluding one offs the operating EBITDA margins stood at 24.0% versus 22.7% in Q2FY24.
  • Operating EBITDA margins (basis gross revenues) for H1FY25 were 18.9% compared to 18.3% in H1FY24.
  • Continuing with its network expansion strategy, primarily the addition of new customer touch points (CTPs); Total CTPs as on 30th September 2024 stood at 4085.
  • In Q2FY25, Agilus conducted ~11.11 million tests versus ~10.59 Mn tests in Q2FY24.
  • The preventive portfolio revenues in Agilus’ overall revenues grew 20% in Q2FY25 and contributed 12% to the operating revenues versus 10% in Q2FY24.

Ashutosh Raghuvanshi, MD and CEO, Fortis Healthcare, said: “We have continued our positive momentum in Q2 with the hospital business contributing approximately 82% to our consolidated EBITDA. We are making good progress on our plans to add nearly 700 beds this fiscal year across key facilities, including Faridabad, Anandpur, Shalimar Bagh, and Noida. Commensurate with our expansion plans, our 350-bed Manesar facility which we acquired in FY24 was commissioned recently. Leveraging our robust balance sheet, we would actively pursue further inorganic growth opportunities in our focus geographic clusters.”

“Among our key specialties, Oncology and Neuro Sciences grew by a strong 19% and 17%, respectively, compared to the same period last year. As part of our ongoing efforts to enhance our medical infrastructure, FMRI introduced the first MR LINAC in North and Central India in September. On the diagnostics business we are moving ahead to consolidate our stake in Agilus by acquiring the 31.52% stake from the PE investors. The diagnostics business performance is witnessing a steady recovery with relatively improving topline growth and better EBITDA margins. However, the business is still impacted by rebranding expenses which we expect will taper off towards the end of the fiscal”

Result PDF

Healthcare Facilities company Fortis Healthcare announced Q1FY25 results:

  • Consolidated Revenues increased 12.2% to Rs 1,859 crore
  • Consolidated Operating EBITDA up 25.5% to Rs 343 crore, Margin 18.4%
  • Hospital Business Revenues increased 14.4% to Rs 1,549 crore; Operating EBITDA up 39.0% to Rs 287 crore, 18.5% Margin
  • The Company’s net debt as of 30th June 2024 stood at Rs 308 crore with a Net Debt to EBITDA of 0.22x as compared to the 0.35x as on 30th June 2023 (basis Q1 annualized EBITDA). Net debt to equity was at 0.04x versus 0.05x as on 30th June 2023.

Ravi Rajagopal, Chairman, Board of Directors, Fortis Healthcare stated, “The mainstay of our performance continues to be the hospital business which presently contributes approx. 84% to our consolidated EBITDA. We are progressing well on our plans to add capacity of close to 700 beds in this fiscal year across our key facilities including Faridabad, Anandpur, Shalimar Bagh and Noida and will also be shortly commissioning the 350 bed Manesar facility which we acquired in FY24. In addition, given the Company’s strong Balance Sheet, we continue to evaluate inorganic growth opportunities in our key focus clusters. The diagnostics business performance is lower than the corresponding previous quarter, largely due to the impact of brand change but has witnessed signs of early improvement versus the trailing quarter. The new brand is being well accepted and gaining prominence; placing the business in a better position to further scale up its performance.”

Commenting on the results for the quarter and the year, Ashutosh Raghuvanshi, MD and CEO, Fortis Healthcare stated, “We have witnessed a good start to the fiscal as reflected in our Q1 earnings. The hospital business continues to show an upward momentum with Operating EBITDA margins expanding 330 bps at 18.5% versus Q1FY24, a growth of 39%. This was primarily led by an increase in occupancy from 64% in Q1FY24 to 67% in Q1FY25 and a higher ARPOB. Most of our key facilities have performed well noticeably Mulund, Anandpur, BG Road and Shalimar Bagh. Amongst our focus specialties Neuro Sciences and Oncology have grown a robust 23% and 22% respectively versus the corresponding previous period. We have strengthened our clinical talent in the medical specialties of Cardiac Sciences, Neurology and Orthopaedics in the quarter and have also commissioned South Asia’s first Gamma Knife Espirit radiosurgery equipment for neurosurgical treatment at FMRI. On the diagnostics business while revenues remain muted, Operating EBITDA margins are better than the trailing quarter showing signs of a gradual recovery which we expect to continue through FY25.”

Result PDF

Fortis Healthcare announced Q4FY24 & FY24 results:

  • Q4FY24 Consolidated Revenues increase 8.7% to Rs 1,786 crore
  • Consolidated Operating EBITDA up 40.5% to Rs 380 crore, 21.3% Margin
  • Hospital Business Revenues increase 10.3% to Rs 1,490 crore; Operating EBITDA up 50.6% to Rs 333 crore, 22.4% Margin
  • FY24 Consolidated Revenues increase 9.5% to Rs 6,893 crore
  • Consolidated Operating EBITDA up 15.1% to Rs 1,268 crore, 18.4% Margin
  • Hospital Business Revenues increase 11.3% to Rs 5,686 crore; Operating EBITDA up 22.7% to Rs 1,058 crore, 18.6% Margin
  • Board recommends dividend of Rs 1 per share (10% of Face Value)
  • The Company’s net debt as of 31st March 2024 stood at Rs 264 crore with a Net Debt to EBITDA of 0.17x as compared to the 0.30x as on 31st March 2023. (basis Q4 annualized EBITDA). Net debt to equity was at 0.03x versus 0.04x as on 31st March 2023.
  • At the consolidated level, cash flow from operations for FY24 stood at Rs 1,100 crore

Ravi Rajagopal, Chairman, Board of Directors, Fortis Healthcare stated, “We have witnessed yet another year of healthy growth and profitability, reflected in the Board recommending a dividend of Rs 1 per share (10% of face value) to shareholders. This signifies the Company’s strengthening fundamentals and continuing growth prospects.

I’m pleased to share that the Company has progressed well on its strategic growth levers viz. brownfield bed expansion, portfolio rationalization and investments in medical equipment and clinical programs. Plans to ramp up current bed capacity are on track and could potentially see the Company reach a total of 5,948 beds over the next few years. We have added 246 beds in FY24 across our network and in line with our portfolio optimization strategy, have also successfully divested two of our underperforming assets in Chennai. With a focus on increasing our presence in specialities such as oncology, neurosciences and cardiac sciences, we have expanded our clinical offerings and medical programs backed by high quality clinical talent. Providing best in class clinical outcomes and a superior patient experience remain critical to our success and these are being further supplemented by digital technologies such as Electronic Medical Records (EMR) system which is gradually being rolled out across our network.

While challenges remain in the diagnostics business primarily as a result of the brand name change; the industry is witnessing signs of stabilization and gradual improvement. We believe that Agilus is well placed given its scale and size to improve its business performance going forward. The Company’s Balance Sheet remains robust enabling us to actively evaluate inorganic opportunities to further accelerate our growth momentum. I’m optimistic that with the continuing support of all our stakeholders we would progressively strengthen our performance in both the hospitals and diagnostics businesses.”

Commenting on the results for the quarter and the year, Ashutosh Raghuvanshi, MD and CEO, Fortis Healthcare stated, “The year gone by has witnessed a healthy performance led by our hospitals business. Our consolidated topline grew 9.5% to Rs 6,893 crore while our operating profitability. i.e. EBITDA increased 15.1% to Rs 1,268 crore. The hospital business contributed more than 80% to our consolidated topline while at the EBITDA level the hospital business contribution rose from 79% in FY23 to 83% in FY24.

For the quarter our hospital business revenues increased 10.3% while margins improved to 22.4% versus 16.4% in Q4FY23.The performance for the quarter was in part due to an improved specialty mix reflected in the YoY ARPOB increase of 10.3% to Rs 2.32 crore.

The year witnessed bed additions in key facilities such as in Anandpur (Kolkata), Mohali (Punjab), BG Road (Bengaluru) and Mulund (Mumbai); in addition to the commissioning of a new 70-bed facility in Ludhiana. We expect to add 700 beds in the current year out of which we plan to operationalize approx. 300 beds. This would also include the soon to be commissioned 450 bed potential Manesar, Gurugram facility which would further strengthen our presence in one of our key clusters .i.e. NCR. In order to provide advanced treatment options to our patients; we continue to upgrade our medical infrastructure, having commissioned LINACs, Cath Labs, MRI, Ortho Robots, Digital PET CT and Da Vinci Robotic Systems in a number of our facilities.

On our diagnostics business, we believe that Agilus has the potential to scale up significantly from current levels and efforts are on to strengthen its business imperatives in terms of its channel / network presence and product portfolio to drive revenues and optimize costs. I’m hopeful that both our business will further build on their FY24 performance in the current year”

Result PDF

Fortis Healthcare announced Q3FY24 & 9MFY24 results:

  • Q3FY24 Highlights:
    • Hospital business revenues increased 9.6% versus the corresponding previous quarter, led by a 10.6% increase in ARPOB to Rs 2.23 crore.
    • Q3FY24 hospital business revenues were at Rs 1,389.5 crore versus Rs 1,267.4 crore in Q3FY23 and Rs 1,452.6 crore in Q2FY24.
    • Occupancy stood at 64.0% in Q3FY24 versus 66.1% in Q3FY23, owing to an increase in the operational beds by ~100, while the occupied beds remained flat YoY. Occupancy levels on a like-to-like basis were at similar levels.
    • ARPOB grew 10.6% to Rs 2.23 crore for Q3FY24 from Rs 2.02 crore in Q3FY23.
    • Q3FY24 diagnostics business gross revenues were at Rs 330.7 crore versus Rs 331.5 crore in Q3FY23.
    • Net debt to EBITDA was at 0.45 vs 0.41 (basis annualized EBITDA of Q3FY24 and Q3FY23, respectively). Net debt was at Rs 518 crore as of December 31, 2023, versus Rs 471 crore as of December 31, 2022.
  • 9MFY24 Highlights:
    • 9MFY24 consolidated revenues were at Rs 5,107.0 crore, up 9.7% versus 9MFY23. The operating margins for 9MFY24 were 17.4%, lower than the 17.8% in the corresponding previous period.
    • 9MFY24 hospital business revenues grew 11.7% to Rs 4,196.2 crore as compared to Rs 3,756.8 crore in 9MFY23. Operating margins stood at 17.3% for the period versus 17.1% in the corresponding previous period.
    • 9MFY24 diagnostic business gross revenues were at Rs 1,033.6 crore versus Rs 1,015.3 crore in 9MFY23.

Ravi Rajagopal, Chairman, Board of Directors, Fortis Healthcare stated, “The quarter’s performance has been led by the hospital business which continues to show a YoY improvement in margins. Plans for incrementally adding to our existing bed capacity by almost 50% are progressing and when operationalized will eventually see some of our key facilities such as Shalimar Bagh, FMRI, Mohali, and BG Road becoming more than 450 beds each. We are also further augmenting our clinical talent and medical infrastructure. In addition, we continue to supplement our expansion plans inorganically with the acquisition of assets such as the 350-bed hospital in Manesar, NCR, and adjunct land parcels to our existing facilities such as the recent one in Kolkata. We have also successfully rationalized our portfolio having divested two of our lossmaking facilities in Chennai; the Arcot Road Vadapalani facility in July 2023 and the Fortis Malar facility in February 2024; thereby improving the profitability of the company”.

Commenting on the results for the quarter, Dr Ashutosh Raghuvanshi, MD and CEO, Fortis Healthcare stated, “The healthy performance in the hospital business which contributes approx. 88% to overall consolidated EBITDA has largely offset the muted performance of the diagnostics business. Our ARPOB continues to show robust growth touching Rs 2.23 crore, an increase of 10.6%. We have commissioned a state-of-the-art medical equipment; the likes of AI-enabled cath labs, surgical robots, and advanced neuro-sciences labs in facilities such as Noida, Anandpur, and Faridabad. Our expansion strategy continues to focus on deepening our cluster presence with the launch of a new 70-bed facility in Ludhiana. This is the second facility in Ludhiana and the fourth in Punjab taking our total bed count in the state to approx. 800. Focus on retaining and attracting high-quality clinical talent remains a priority with the quarter witnessing clinicians from key specialties such as cardiology, oncology, and neurology joining the Fortis network. Our efforts on digital transformation are progressing well with the EMR (Electronic Medical Records) program implementation underway and revenues from digital channels witnessing a robust growth of over 30%”.

 

Result PDF

Fortis Healthcare announced Q2FY24 & H1FY24 results:

  • Q2FY24:
    • Consolidated revenues at Rs 1,770 crore, up 10.1%
    • Operating EBITDA at Rs 330 crore, 18.6% margin
    • Hospital Business Q2FY24 revenues up 12% to Rs 1,453 crore
    • Operating EBITDA at Rs 268 crore, 18.4% margin
    • Hospital business ARPOB increases 11.8% to Rs 2.21 crore
    • Agilus Diagnostics files DRHP for a proposed IPO
  • H1FY24:
    • Consolidated revenues were at Rs 3,427.4 crore, up 10.7% versus H1FY23. The operating margins for H1FY24 were 17.6%, marginally lower than the 17.9% in the corresponding previous period.
    • Hospital business revenues grew 12.7% to Rs 2,806.7 crore as compared to Rs 2,489.3 crore in H1FY23. Operating margins stood at 16.9% for the period versus 17.3% in the corresponding previous period.
    • Diagnostic business gross revenues were at Rs 702.9 crore versus Rs 683.8 crore in H1FY23

Ravi Rajagopal, Chairman, Board of Directors, Fortis Healthcare stated, “Our Q2FY24 performance has seen the hospital business profitability increasing both versus the corresponding and trailing quarter. We remain on track to add approx. 250 beds to our network in the current fiscal across facilities such as Mulund, Anandpur, and Ludhiana with a total planned addition of close to 1,400 beds in the next few years. Further augmenting our bed expansion plans in the Delhi – NCR and the Punjab clusters, we are also evaluating new expansion opportunities including optimizing the current available space to add additional beds in Mohali and Shalimar Bagh. Following from the divestment of our Arcot Road, Chennai facility in July 2023, our focus on evaluating further portfolio rationalization opportunity continues. Efforts to implement the EMR technology are ongoing and offer a platform to integrate this with our HIS, myFortis app, and other applications. This could enable us to digitize the patient journey and provide a ‘Personalized Experience’ to our patients. I’m pleased to highlight that in September 2023 we filed the Draft Red Herring Prospectus (DRHP) for a proposed IPO of Agilus Diagnostics, our diagnostics business vertical.”

Commenting on the results for the quarter, Dr Ashutosh Raghuvanshi, MD and CEO, Fortis Healthcare stated, “Our consolidated revenues in Q2FY24 have grown 10.1% to Rs 1,770 crore with operating EBITDA margins at 18.6%. Our hospital business has seen a significant improvement versus the trailing quarter with margins expanding 320 bps and are also better than Q2 of the previous year. Operating margins in the hospital business were at 18.4%, better than 18.2% on a YoY basis. This is attributable in part to a stronger case mix and growth in medical tourism revenues. Our focus on improving our specialty mix has led to a 13.4% growth cumulatively in our top 6 specialties with surgical contribution improving to 61.2% versus 60.5% in Q2 of the previous year. This is also reflected in the 11.8% growth witnessed in ARPOB which stood at Rs 2.21 crore. We have commissioned new medical equipment such as LINAC and Ortho Robots at select facilities such as Noida, Shalimar Bagh, and FMRI and have further bolstered our clinical talent; onboarding clinicians in several specialties including amongst others Oncology, Neurology, and Renal Sciences. These along with our brownfield bed expansion plans and a continuing focus on inorganic opportunities are expected to drive further growth in the business.”

Result PDF

Fortis Healthcare announced Q1FY24 results:

  • Consolidated revenues for Q1FY24 at Rs 1,657 crore vs Rs 1,488 crore in Q1FY23, a growth of 11.4%
  • Consolidated operating EBITDA at Rs 273 crore versus Rs 251 crore, a growth of 8.7%
  • PBT before exceptional items at Rs 169 crore versus Rs 176 crore
  • PAT before exceptional items at Rs 122 crore versus Rs 134 crore
  • Diagnostics business of the company was renamed “Agilus Diagnostics Limited”
  • Board of Fortis & Agilus has approved for Agilus to initiate an initial public offer process, by way of an offer for sale
  • Company divests its hospital business at Vadapalani, Chennai, to enhance focus on key strategic clusters.

Ravi Rajagopal, Chairman, Board of Directors, Fortis Healthcare stated, “For Q1FY24, our consolidated revenues grew 11.4% to Rs 1,657.4 crore while our operating margins stood at 16.5% similar to trailing quarter and marginally lower than Q1FY23. More importantly and signifying our intent to move forward, the quarter witnessed key strategic corporate actions related to both our hospitals and diagnostic business. On the hospital side, our portfolio rationalization strategy gained momentum with the divestment of our loss-making Arcot Road facility in Chennai in July 2023. With an impetus on inorganic growth, we acquired a 350 bedded hospital in Manesar, Gurugram, enabling us to further augment our presence in Delhi-NCR. This we expect to close shortly. Our plans for brownfield bed expansion of close to 1400 beds in the next 2-3 years, increasing our focus on key medical specialties such as oncology and attracting the right clinical talent remain on track. We have initiated the name change of the diagnostics business which is now known as Agilus Diagnostics Limited. I’m also pleased to share that the Board of Fortis and Agilus, today, have granted approval for Agilus to initiate an initial public offer process, by way of an offer for the sale of its equity shares, subject to receipt of requisite approvals, market conditions and other considerations.”

 

Result PDF

Trending News

M&M sells 3.6% stake in CIE Automotive S.A.

M&M has informed exchanges that its wholly owned subsidiary i.e. Mahindra Overseas Investment Company (Mauritius) Limited (“MOICML”), has sold its 3.6% stake in CIE Automotive S.A (“CIE Spain”), for a total consideration of ~119 million Euros (~₹ 1,250 crore). 

Published on 05-Dec-2025 09:08

Zydus gets clean bill from USFDA for injectable facility.

Zydus has received the Establishment Inspection Report (EIR) from the USFDA for a GMP follow-up inspection conducted at its injectable facility located at Jarod, Vadodara classifying the facility as Voluntary Action Indicated (VAI). 

Published on 05-Dec-2025 09:07

GlaxoSmithKline aims to double revenue in 4-5 years through specialty growth

In the media GlaxoSmithKline Pharmaceuticals India MD Bhushan Akshikar shared plans for a major revival, targeting a revenue doubling to ~₹8,000 crore in 4–5 years by shifting from its legacy general medicines to high-growth specialty areas like oncology, liver diseases, and adult vaccination. 

Published on 05-Dec-2025 09:06

HCG sets ambitious expansion and margin targets

HealthCare Global Enterprises (HCG) new team has outlined a 4–5-year roadmap to unlock its ~₹4,000 crore network potential, add 1,000 beds, and drive 300–400 bps EBITDA margin improvement through operational synergies. 

Published on 05-Dec-2025 09:05

India-Russia agree on major defence and space deals

During Russian President Vladimir Putin's official visit to India, multiple significant agreements and deals are expected to be discussed or signed today, across the defence and space sectors. 

Published on 05-Dec-2025 09:04

TARIL bags ₹53 crore PGCIL HVDC transformer order

Transformers and Rectifiers (India) Limited (TARIL) secured a key domestic order worth ₹53.33 Crore from the Power Grid Corporation of India Limited (PGCIL). 

Published on 05-Dec-2025 09:03

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app
✕
Application status